2.00Open1.85Pre Close100 Volume23 Open Interest7.00Strike Price20.00KTurnover64.08%IV1.58%PremiumDec 20, 2024Expiry Date1.86Intrinsic Value100Multiplier19DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.9562Delta0.0719Gamma4.66Leverage Ratio-0.0039Theta0.0034Rho4.46Eff Leverage0.0019Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet